USP7 cooperates with NOTCH1 to drive the oncogenic transcriptional program in T cell leukemia
Kelly M. Arcipowski,
Carlos A. Martinez,
Blanca Teresa Gutierrez Diaz,
Kenneth K. Wang,
Megan R. Johnson,
Andrew G. Volk,
Paul M. Thomas,
Young Ah Goo,
Nebiyu A. Abshiru,
Stacy A. Marshall,
Emily J. Randleman,
Clayton K. Collings,
Pieter Van Vlierberghe,
Neil L. Kelleher,
John D. Crispino,
Posted 16 Jan 2018
bioRxiv DOI: 10.1101/248427 (published DOI: 10.1158/1078-0432.CCR-18-1740)
Posted 16 Jan 2018
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease, affecting children and adults. Treatments show high response rates but have debilitating effects and carry risk of relapse. Previous work implicated NOTCH1 and other oncogenes. However, direct inhibition of these pathways affects healthy tissues and cancer alike. Here, we demonstrate that ubiquitin-specific protease 7 (USP7) controls leukemia growth by stabilizing the levels of the NOTCH1 and JMJD3 demethylase. USP7 is overexpressed T-ALL and is transcriptionally regulated by NOTCH1. In turn, USP7 controls NOTCH1 through deubiquitination. USP7 is bound to oncogenic targets and controls gene expression through H2B ubiquitination and H3K27me3 changes via stabilization of NOTCH1 and JMJD3. We also show that USP7 and NOTCH1 bind T-ALL superenhancers, and USP7 inhibition alters associated gene activity. These results provide a new model for deubiquitinase activity through recruitment to oncogenic chromatin loci and regulation of both oncogenic transcription factors and chromatin marks to promote leukemia. USP7 inhibition significantly blocked T-ALL cell growth in vitro and in vivo. Our studies also show that USP7 is upregulated in the aggressive high-risk cases of T-ALL and suggest that USP7 expression might be a prognostic marker in ALL and its inhibition could be a therapeutic tool against aggressive leukemia.
- Downloaded 1,203 times
- Download rankings, all-time:
- Site-wide: 22,587
- In cancer biology: 535
- Year to date:
- Site-wide: 122,819
- Since beginning of last month:
- Site-wide: 124,156
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!